Acadia Healthcare Q4 2019 Earnings Report
Key Takeaways
Acadia Healthcare reported Q4 2019 revenue of $780.2 million, a 4.9% increase year-over-year. The company experienced a net loss of $11.3 million, or $0.13 per diluted share. U.S. facilities showed improvement, and the company is proceeding with the sale of its U.K. business.
Revenue for the fourth quarter was $780.2 million, up 4.9% from Q4 2018.
Net loss attributable to Acadia stockholders was $11.3 million, or $0.13 per diluted share.
U.S. same facility revenue increased 5.5%, driven by increases in patient days and revenue per patient day.
A formal process was launched regarding the sale of the U.K. business.
Acadia Healthcare
Acadia Healthcare
Acadia Healthcare Revenue by Geographic Location
Forward Guidance
Acadia provided financial guidance for the full year 2020, including revenue, adjusted EBITDA, and adjusted earnings per diluted share. The company also provided guidance for the first quarter of 2020.
Positive Outlook
- Revenue in a range of $3.28 billion to $3.34 billion
- Adjusted EBITDA in a range of $610 million to $630 million
- Adjusted earnings per diluted share in a range of $2.20 to $2.40
- Revenue in a range of $795 million to $805 million for Q1 2020
- Adjusted earnings per diluted share in a range of $0.37 to $0.42 for Q1 2020
Challenges Ahead
- Guidance does not include the impact of any future acquisitions, divestitures or transaction-related expenses
- Potential difficulties operating our business in light of political and economic instability in the U.K.
- The impact of fluctuations in foreign exchange rates, including the devaluation of the British Pound Sterling (GBP) relative to the U.S. Dollar (USD)
- Acadia’s efforts to sell its U.K. operations may not result in any definitive transaction or enhance stockholder value
- Potential reductions in payments received by Acadia from government and fourth-party payors
Revenue & Expenses
Visualization of income flow from segment revenue to net income